Shares of Cancer Genetics Inc. (CGIX) are soaring over 213% in pre-market today, after the company announced a definitive merger agreement with StemoniX Inc.
CGIX has been trading in the range of $1.92 - $9.50 for the past one year, and closed Friday's trade at $2.91, down 15 cents or 4.90%. The stock is currently trading at $9.12, up $6.21 or 213.40% in the pre-market session Monday.
StemoniX, a private company, develops high-throughput disease-specific human organoid platforms integrated with leading-edge data science technologies. Under the terms of the merger agreement, StemoniX would merge with a newly formed subsidiary of Cancer Genetics in an all-equity transaction.
Upon shareholder approval, the combined company expects to remain listed on the Nasdaq Stock Market. StemoniX would retain its name and become a wholly-owned subsidiary of Cancer Genetics.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.